{"id":"sodium-ozagrel","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_fixedAt":"2026-03-30T11:54:22.677587","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ozagrel is a thromboxane A2 (TXA2) synthetase inhibitor that blocks the production of thromboxane A2, a potent platelet aggregator and vasoconstrictor. By reducing TXA2 levels, the drug decreases platelet aggregation and prevents thrombotic events. This mechanism makes it useful in preventing ischemic complications in cardiovascular and cerebrovascular conditions.","oneSentence":"Sodium ozagrel inhibits thromboxane A2 synthetase, reducing platelet aggregation and thrombosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:37:54.689Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke"},{"name":"Prevention of thrombotic events in cardiovascular disease"}]},"_fixedFields":["modality→Small Molecule"],"trialDetails":[{"nctId":"NCT00200356","phase":"PHASE4","title":"Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2004-08","conditions":"Cerebral Infarction","enrollment":401}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"CEREBRAL INFARCTION"},{"count":2,"reaction":"ANAPHYLACTIC SHOCK"},{"count":2,"reaction":"CHEST PAIN"},{"count":2,"reaction":"VISION BLURRED"},{"count":1,"reaction":"ABDOMINAL PAIN LOWER"},{"count":1,"reaction":"ARTERY DISSECTION"},{"count":1,"reaction":"ARTHRALGIA"},{"count":1,"reaction":"BACK PAIN"},{"count":1,"reaction":"BLOOD PRESSURE DECREASED"},{"count":1,"reaction":"BLOOD PRESSURE FLUCTUATION"}],"_approvalHistory":[],"publicationCount":44,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Sodium Ozagrel","genericName":"Sodium Ozagrel","companyName":"Tanabe Pharma Corporation","companyId":"tanabe-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sodium ozagrel inhibits thromboxane A2 synthetase, reducing platelet aggregation and thrombosis. Used for Acute ischemic stroke, Prevention of thrombotic events in cardiovascular disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}